The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR
- Shuai Zhao†1, 2,
- Yang Cao†1, 2,
- Shi-bo Liu†1, 2,
- Xu-an Wang1, 2,
- Run-fa Bao1, 2,
- Yi-jun Shu1, 2,
- Yun-ping Hu1, 2,
- Yi-jian Zhang1, 2,
- Lin Jiang1, 2,
- Fei Zhang1, 2,
- Hai-bin Liang1, 2,
- Huai-feng Li1, 2,
- Qiang Ma1, 2,
- Yi Xu1, 2,
- Zheng Wang1, 2,
- Yi-chi Zhang1, 2,
- Lei Chen3Email author,
- Jian Zhou3Email author and
- Ying-bin Liu3Email author
© The Author(s). 2016
Received: 13 March 2016
Accepted: 2 June 2016
Published: 18 June 2016
Gallbladder carcinoma (GBC) is the most common malignancy of the bile duct and patients with GBC have extremely poor prognoses. PIK3CA, which encodes the phosphoinositide 3-kinase (PI3K) subunit p110α, is frequently mutated in many cancers, including GBC. The function of the E545K mutation in GBC is not fully understood.
E545K mutation was determined in human GBC tissues by targeted sequencing. The effects of E545K mutation and PI3K selective inhibitor, A66 on GBC cells were evaluated using Cell Counting Kit-8 (CCK-8) cell Viability and transwell assays. The mechanisms of E545K mutation and A66 were analyzed by western blot and co-immunoprecipitation (Co-IP) assay. Subcutaneous xenograft models in nude mice were employed to evaluate the role of E545K mutation and A66 in GBC progression.
The rate of PIK3CA E545K mutation in GBC patients was 6.15 %. And the survival of GBC patients was correlated with E545K mutation significantly (P < 0.05). The E545K mutation promoted proliferation, migration and invasion of GBC cells in vitro and tumor proliferation in vivo. A66 suppressed proliferation of GBC cells in vitro and tumor proliferation in vivo.
The prognoses of patients with E545K mutation were worse than patients without this mutation. The E545K mutation promoted GBC progression through enhanced binding to EGFR and activating downstream akt activity. The PI3K selective inhibitor, A66, suppressed gallbladder carcinoma proliferation.
Gallbladder carcinoma (GBC) is the most common malignancy of the bile duct and the fifth most common gastrointestinal cancer [1, 2]. Patients with GBC have extremely poor prognoses, and their 5-year survival rate is less than 10 % [3, 4]. There is currently no effective drug for the treatment of patients with GBC, thus, novel effective drugs are urgently needed to improve the prognoses of these patients. Precision-medicine has been deemed increasingly important for clinical treatment , and the identification of the mechanisms of the development and progression of GBC is needed to improve the prognoses of patients with GBC.
Phosphoinositide 3-kinases (PI3Ks) are key components of cell signaling pathways that regulate proliferation and apoptosis and play important roles in the proliferation, invasion and metastasis of cancer cells [6, 7]. Stimulated by upstream receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCRs), PI3Ks transduce signals into intracellular messages that then activate AKT and other downstream effector pathways . Class Ia PI3Ks have been widely studied and are thought to have the most important effects among all PI3Ks . Class Ia PI3Ks contain a p110 catalytic subunit and a p85 regulatory subunit. Three homologous p110 catalytic isoforms (p110α, p110β and p110δ) are encoded by three different genes: PIK3CA, PIK3CB and PIK3CD. The p110α and p110β subunits are ubiquitously expressed, whereas the p110δ subunit is largely restricted to the immune system in mammals . Upon growth factor stimulation, p110α binds to the phospho-tyrosine residues of receptor protein kinases or adaptor proteins through interactions with p85 and subsequently activates the lipid kinase activity of p110α . Activated p110α converts phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3), and PIP3 subsequently activates the downstream AKT signaling pathway as a second messenger [9, 10]. Recent cancer studies have revealed that many components of the PI3Ks, including p110α, are frequently targeted by germline or somatic mutations in a variety of human cancers. These findings and the fact that PI3Ks are highly suited for pharmacologic intervention make the PI3K pathway one of the most attractive targets for therapeutic cancer interventions . Numerous PI3K inhibitors have been tested in clinical trials in recent years, however, inhibitor resistance has been widely observed [12–15]. Most somatic PIK3CA mutations in human cancers occur within two hot spots: E545K and H1047R. The E545K mutation of PIK3CA was first reported in 2005 . Previous studies have identified the E545K mutation of PIK3CA in various carcinomas, including colorectal cancer, glioblastoma, gastric cancer, breast cancer, lung cancer , esophageal squamous cell cancer , pancreatic cancer , intrahepatic cholangiocarcinoma  and GBC . Recently, we found that E545K is the only missense mutation of PIK3CA in GBCs based on whole-exome and targeted genesequencing . The function of the E545K mutation in GBC cells is not been fully understood.
In this study, we analyzed the PIK3CA E545K mutation in a cohort of GBC samples and explored the function of the PIK3CA E545K mutation in GBC. Moreover, we tested the effect of a PI3K inhibitor on GBC.
Patients with GBC harboring the E545K mutation exhibit worse prognoses
Relationships of the PIK3CA E545K mutation with the clinicopathological characteristics of the GBCs
PI3K E545K mutation status
No.of positive cases (%)
3 (5 %)
5 (7.14 %)
3 (4.92 %)
5 (7.25 %)
Lymph node metastasis
4 (4.65 %)
4 (9.09 %)
0 (0 %)
6 (5.94 %)
2 (9.52 %)
5 (7.04 %)
3 (5.08 %)
6 (6.59 %)
2 (5.13 %)
PIK3CA is vital for the proliferation, migration, invasion and clone formation of GBC cells in vitro
To investigate the function of PIK3CA in GBC, we knocked down PIK3CA in GBC cell lines. We assessed PIK3CA expression in 6 GBC cell lines and found that the expression quantities in the 6 GBC cell lines were similar (Additional file 1: Figure S1a). The GBC-SD and NOZ cell lines were used in following experiments. Three different siRNAs were designed to knockdown PIK3CA (Additional file 1: Figure S1b, c). siRNA2 (referred to as siRNA below) exhibited the greatest knockdown efficiency and was therefore used in the following experiments.
The E545K mutation of PIK3CA promotes GBC progression in vitro
To determine whether the E545K mutation of PIK3CA affects GBC progression, we transfected PIK3CA-WT and PIK3CA-E545K plasmids into GBC-SD and NOZ cells. We conducted reverse transcription polymerase chain reaction (RT-PCR) and Western blot and observed similar PI3K p110α expression levels in PIK3CA-E545K and PIK3CA-WT cells (Additional file 1: Figure S2a-c).
The E545K mutation of PIK3CA increased downstream Akt activity
Based on the experiments described above, we found that E545K-PIK3CA and WT-PIK3CA cells exhibited abnormal cytological and protein behaviors. These findings suggested that the E545K mutation may enhance the activity of the PI3K-Akt pathway. Therefore, we investigated total-Akt and p-Akt expression. As expected, p-Akt expression in the E545K was higher than WT (Fig. 4h, i), indicating that the E545K mutation improved Akt activity.
The E545K mutation enhanced the binding of PI3K p110α to epidermal growth factor receptor (EGFR)
After obtaining the above results, we further sought to examine how the E545K mutation increased Akt activity. P110α exerts its effects via recruitment to the membrane via the interaction of the p85 subunit with the tyrosine phosphate motifs receptors that are activated in response to growth factor stimulation and the subsequent activation of RTKs [9, 10]. EGFR is a primary member of the ERBB family, which is a group of extremely important RTKs. To explore the potential mechanism underlying our findings, we hypothesized that the E545K mutation enhances p110α binding to EGFRs and subsequently increases PI3K-Akt pathway activity.
A selective PI3K p110α inhibitor suppressed GBC progression in both WT and E545K cells in vitro
Considering the increased activity of Akt in the E545K compared with WT cells and the worse prognosis of GBC patients harboring the E545K mutation, we sought to determine whether a PI3K inhibitor was effective in patients with the E545K mutation to satisfy the requirement of precision medicine. We selected A66, which is a widely used selective PI3K p110α inhibitor, to perform the follow-up experiments. We first measured the half maximal inhibitory concentration (IC50) of A66 in GBC cell lines and identified values of 15 μM/L A66 for the GBC-SD cells and 5 μM/L A66 for the NOZ cells in the in vitro experiments detailed below (Additional file 1: Figure S3a, b). IC50 of A66 was from 0.1 to 10 μM/L in various cells in published literatures [22–24].
The E545K mutation promoted GBC progression and the selective p110α inhibitor suppressed GBC progression in vivo
We also tested the effect of the selective PI3K p110α inhibitor in vivo. Three weeks after the transplantation of the tumor cells, the mice were injected with 1 mg A66 every 3 days for 3 weeks. We found that the tumor volumes and weights of the mice injected with A66 were obviously reduced compared with mice injected with normal saline (NS, Fig. 7c). Immunohistochemical staining for tumors resected from mice treated with A66 or NS was used to analyze tumor proliferation status. We found positive ratios of Ki67 in WT and E545K tumors treated with A66 were higher than in tumors treated with NS significantly (Fig. 7d, e), and representative photomicrographs were shown. Furthermore, we found expression quantity of PI3K p110α in WT and E545K tumors treated with A66 or NS was similar (Fig. 7d). These results demonstrate that the selective PI3K p110α inhibitor significantly suppressed GBC progression following the transplantation of both WT and E545K cells.
GBC is a highly fatal disease, thus, the mechanisms of GBC development and progression require urgent elucidation to identify new early diagnostic methods and novel drugs to improve the prognoses of patients with GBC [25, 26]. PI3Ks are widely known to play crucial roles in both normal cells and cancer cells [6, 7, 27]. Abnormal activation of the PI3K-akt pathway frequently leads to tumor development and progression [7, 27]. Numerous PI3K inhibitors have been tested in clinical trials, and inhibitor resistance has been observed. Hence, the unknown mechanism associated with the PI3K-akt pathway has aroused substantial interest among researchers. The PIK3CA E545K mutation has been identified in numerous cancers [17–21].
We followed up 130 patients with GBC for 36 months after surgery and found that the E545K mutation was associated with overall survival. The patients with the E545K mutation had significantly worse prognoses than the patients without this mutation. We did not identify any significant associations of the PIK3CA E545K mutation with the clinical data. The possible cause is that the sample size was not sufficiently large to reveal such relationships.
The knockdown of PIK3CA significantly suppressed GBC cell proliferation, migration, invasion and clone formation, and the overexpression of PIK3CA obviously promoted these processes in vitro. These findings conclusively demonstrated the vital function of PIK3CA in GBC cells. Compared with the WT PIK3CA, the PIK3CA with the E545K mutation exhibited stronger effects on cell proliferation, migration, invasion and clone formation. Similarly, the E545K mutation exhibited a stronger tumor proliferation-enhancing effect than the WT in vivo. These findings are in agreement with discoveries related to other tumors [8, 28]. We found that the phosphorylated form of akt was elevated in the E545K mutants compared with the WTs, but the expression of PIK3CA was similar in the WT and E545K cells. PI3K p110α (encoded by PIK3CA) and PI3K p110β (encoded by PIK3CB) play similar roles in the PI3K-akt pathway, but the activity of p110α is greater than that of p110β . Therefore, we hypothesized that the E545K mutation could enhance the ability of p110α to bind to upstream RTKs. We subsequently quantified the p110α binding to EGFR (which is one of the most important RTKs) in WT and E545K cell lines using co-immunoprecipitation (CO-IP). Interestingly, we observed greater binding of p110α to EGFR in the E545K cells than in WT cells, although p110α expression was similar in the WT and E545K cell lines. Together, these results demonstrated that the E545K mutation of PIK3CA promotes tumor progression in GBC via enhancement of the binding to EGFR. The E545K and H1047R mutations of PIK3CA increase PIP3 levels, activate akt signaling and induce cellular transformation [7, 29, 30], but the exact molecular mechanism by which these mutations activate p110α has not been determined. Some studies have demonstrated that, the regulatory p85 subunit stabilizes the catalytic p110α subunit and inhibits its enzymatic activity in the basal state . The p110α subunit contains an N-terminal adaptor-binding domain, a Ras-binding domain, a C2 domain, a helical domain, a catalytic domain, moreover, the helical domain is related to the interaction with p85 . The mechanism that is currently thought to explain the oncogenic effect of the E545K mutation is that the helical domain mutation weakens p110α’s interactions with the p85 regulatory subunits, which attenuates the inhibitory effect of p85 and thus increases the enzymatic activity of p110α [33, 34] Moreover, another study suggested that the weakened p110α-p85 interaction caused by the mutation is not sufficient for the p110α mutant proteins to exert their oncogenic functions and provided several pieces of evidence that the p110α E545K-IRS1 interaction plays a critical role in tumorigenesis . Our study advanced the explanation of the oncogenic effect of the E545K mutation by demonstrating that this mutation promotes tumor progression through enhanced binding to EGFR in GBC.
Because patients with the E545K mutation have worse prognoses than those without this mutation, we believe that the needs of patients with E545K mutation for new effective drugs is greater than that of patients without the mutation. Although numerous PI3K inhibitors have been tested in clinical trials, no drugs are available that target the E545K mutation. We are convinced that the efficacy of these drugs should be confirmed in clinical trials involving patients with the E545K mutation based on the precision medicine perspective. Some studies have reported that selective inhibitors may have better application potentials due to their lower toxicities . Therefore, we tested a selective inhibitor of PI3K p110α (A66) in vivo and in vitro. Interestingly, we found that A66 significantly suppressed tumor proliferation in both WT and E545K cells lines.
In this study, we found that patients with E545K mutation had worse prognoses than those without this mutation and confirmed that the E545K significantly promoted tumor progression both in vitro and in vivo. Excitingly, the PI3K inhibitor was effective against the E545K mutation. Considering the lethality of GBCs and highly malignant effect of PIK3CA E545K, we believe that the early use of effective drugs following gene sequencing may represent an efficacious method for improving the prognoses of GBC patients harboring the PIK3CA E545K mutation.
The prognoses of patients with E545K mutation were worse than patients without this mutation. The E545K mutation promoted GBC progression through enhanced binding to EGFR and activating downstream akt activity. The PI3K selective inhibitor, A66, suppressed gallbladder carcinoma proliferation.
The GBC tissue specimens were obtained from 130 patients who underwent cholecystectomies from 2008 and 2013 in the Department of General Surgery, Xinhua Hospital. The sequencing technology was provided by BioSune (Shanghai, China). The patients follow-ups were performed via telephone once every three months. This study was approved by the ethics committee of Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University. All patients provided written informed consent.
Cell lines and culture
The human gallbladder cancer cell lines GBC-SD, NOZ, SGC-996, OCUG, EHGB-1 and EHGB-2 were purchased from Shanghai Institute of Cell Biology, Chinese Academy of Sciences (CAS, Shanghai, China). The GBC-SD cells were grown in high-glucose DMEM (Gibco, Grand Island, NY, USA) supplemented with 10 % fetal bovine serum (Gibco) and 1 % penicillin-streptomycin(Hyclone, Logan, UT, USA). The NOZ cells were grown in William’s medium (Gibco) supplemented with 10 % fetal bovine serum (Gibco) and 1 % penicillin-streptomycin (Hyclone). The SGC cells were grown in 1640 medium (Gibco) supplemented with 10 % fetal bovine serum (Gibco) and 1 % penicillin-streptomycin (Hyclone), The OCUG, EHGB-1 and EHGB-2 cells were grown in high-glucose DMEM (Gibco) supplemented with 15 % fetal bovine serum (Gibco) and 1 % penicillin-streptomycin (Hyclone). All cells lines were maintained at 37 °C in a humidified atmosphere with 5 % CO2. The A66 used in the in vitro and in vivo experiments was purchased from Selleck Chemicals (Houston, USA). Before conducting the CO-IP experiments, the GBC-SD and NOZ cells were starved for 12 h and 1 ng/mL EGF (Sangon Biotech, Shanghai, China) was added to the cell culture medium. The cells were maintained for 12 h to eliminate other confounding growth factor signals.
RT-PCR, Q-PCR and sequencing
Total RNA was extracted from the cultured GBC-SD, NOZ, SGC-996, OCUG, EHGB-1, and EHGB-2 cells or tissue samples with Trizol reagent (Takara, Shiga, Japan). cDNA was synthesized from 1 μg of total RNA using random primers and M-MLV Reverse Transcriptase (Takara). The RNA expression quantities were measured by RT-PCR using the SYBR-Green method (Takara) on a StepOnePlus system (Thermo Fisher Scientific, USA) according to the manufacturer’s instructions. The relative expression levels of the target genes were calculated by as 2-ΔCT (ΔCT = CT PIK3CA -CT GADPH) and normalized to the relative expressions detected in the corresponding control cells, which were defined as 1.0. In the present study, the expression levels (defined as the fold changes) of PIK3CA were calculated as 2-ΔΔCT(ΔΔCT = ΔCTsample1-ΔCTsample2). The sequencing service was provided by BioSune (Shanghai, China).
The RT-PCR primer sequences were as follows:
The sequencing Primer sequences were as follows:
Cell transfections with siRNA or plasmid
The siRNAs were synthesized by Biomics (Nantong, China). The siRNA sequences were as follows:
hs-PIK3CA siRNA1 positive-sense strand: 5′-GACACUCUAGUAUCUGGAAdTdT-3′
anti-sense strand: 5′-UUCCAGAUACUAGAGUGUCdTdT-3′
hs-PIK3CA siRNA2 positive-sense strand: 5′-CAGAGUUACUGUUUCAGAAdTdT-3′
anti-sense strand: 5′-UUCUGAAACAGUAACUCUGdTdT-3′
hs-PIK3CA siRNA3 positive-sense strand: 5′-GAGAUGUGUUACAAGGCUUdTdT-3′
anti-sense strand: 5′-AAGCCUUGUAACACAUCUCdTdT-3′
The PIK3CA-WT(wile-type) plasmid and the PIK3CA-E545K mutation plasmid were gifts from Bert Vogelstein  (Addgene plasmid #16643 and #16642, respectively). siRNA or plasmids were transfected into the cells using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instructions.
Western blot and Co-IP analyses
The GBC-SD and NOZ cells were collected with the culture medium into centrifuge tubes. After centrifugation at 1500 r/min for 3 min, the cells were washed twice with cold phosphate-buffered saline (PBS). Then, the cells were lysed with RIPA buffer (Beyotime Institute of Biotechnology, Beijing, China) and protease inhibitor (Roche Applied Science, Indianapolis, IN, USA) at 4 °C for 5 min. After centrifugation at 14,000 r/min at 4 °C for 5 min, the protein concentration was measured using a bicinchoninic acid (BCA) assay kit (Beyotime, Shanghai, China). Equal amounts of protein (40 μg/lane) from the different samples were separated by 10 % sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then electrophoretically transferred to nitrocellulose membranes (Millipore, Bedford, MA, USA). The membranes were blocked with 5 % skim milk for 2 h and then incubated with the primary antibodies against PI3K p110α (CST, Cell Signaling Technology, USA), Bcl-2(Proteintech), Bax(Proteintech), cyclin D1(Proteintech), β-actin(Proteintech), vimentin(Proteintech), E-cadherin(Proteintech), Akt and P-akt (Proteintech) (1:1000) at 4 °C overnight. The membranes were incubated with the secondary antibodies (horseradish peroxidase HRP-conjugated goat anti-rabbit/anti-mouse IgG 1:5000; Abcam, Cambridge, UK) for 2 h after washing three times with TBST buffer. The bands were visualized using a chemiluminescent detection kit (Rockford, IL, USA) and photographed using a Gel Doc 2000 (BioRad, Hercules,CA, USA). The immunoprecipitations were set up as follows: Lysates containing 0.5 mg of total protein were incubated with 1 1 μL of EGFR antibody(CST). All immunoprecipitations were performed overnight, and protein A/G sepharose (Santa Cruz Biotechnology) was added for 2 h. The beads were then collected by centrifugation at 1000 r/min, followed by three washes with lysis buffer. The resulting immunoprecipitates were subjected to Western blot analyses.
Cell proliferation assay
The proliferations of the GBC-SD and NOZ cells lines treated with siRNA, negative control (NC) siRNA (random null siRNA sequence), CON (only Lipofectamine 2000), WT (PIK3CA-WT plasmid), E545K (PIK3CA-E545K plasmid) and vector (empty vector) were measured using a Cell Counting Kit-8 (CCK8, Dojindo, Japan) assay according to the manufacturer’s instructions. The GBC-SD (8 × 104) and NOZ (5 × 104) cells were seeded into 6-well plates (Corning, NY, USA) and incubated overnight. The cells were then transfected with siRNA, NC, CON, WT, E545K or vector. The cells were maintained for 12 h and then seeded into 96-well plates (500 cells in each well). The cells were maintained for 6, 24, 48, 72, 96 and 120 h, and CCK-8 was then added to each well, and cells were incubated at 37 °C for 3 h. The optical densities (ODs) were measured at a wavelength of 450 nm with a microplate reader (QuantBio Tek Instruments, Winooski, VT, USA). The results are represented as averages of five different wells. Cell proliferation was measured according to the following the formula: cell proliferation = (ODDay n/ODDay1)*100 %.
Cell migration and invasion assays
Cell migration and invasion were examined using transwell filters (BD Biosciences, Franklin Lakes, NJ). GBC-SD and NOZ cells were treated with siRNA, NC, CON, WT, E545K or vector same as described above. GBC-SD (2 × 104) and NOZ (1.5 × 104) cells in 200 μL serum-free DMED medium or William’s medium were added to the upper chamber, which contained an uncoated or Matrigel (BD Biosciences)-coated membrane. The lower chamber was filled with 500 μL of basal medium with 10 % fetal bovine serum. After incubation at 37 °C in a humidified 5 % CO2 incubator for 18 h for the siRNA knockdown experiments or 12 h for the plasmid overexpression experiments in the uncoated transwells and 24 h for the siRNA knockdown experiments or 18 h for the plasmid overexpression experiments in the Matrigel-coated transwells, the cells that migrated to the lower compartment were fixed with 4 % paraformaldehyde for 20 min and stained with 0.1 % crystal violet (Sigma-Aldrich) for 30 min. The migrated or invaded cells were counted in five fields (above, below, left, right and middle of the well) in each well. Imaging and cell counting were performed under a microscope (Leica, Wetzlar, Germany).
Colony formation assay
GBC-SD and NOZ cells were treated with siRNA, NC, CON, WT, E545K or vector as what described above. The cells were dispersed as single cell suspensions, and 500 cells per well were planted into 6-well plates. The cells were cultured (5 days for the NOZ cells and 14 days for the GBC-SD cells) to allow for colony formation. Subsequently, the cells were fixed with 4 % paraformaldehyde for 20 min and stained with 0.1 % crystal violet for 30 min. The plates were air-dried after washing and the stained colonies were photographed using a microscope. The total number of colonies (>50 cells/colony) was counted.
Screening of the stable expression cell lines
The PIK3CA-WT and PIK3CA-E545K mutation plasmids were transfected into NOZ cells with Lipofectamine 2000 (Thermo Fisher Scientific). Cell culture medium with 1000 μg/mL G418 was added and then replaced with fresh culture medium with 500 μg/mL G418 every three days. The cells were cultured for two weeks at 37 °C in a humidified atmosphere with 5 % CO2. The cells were diluted to single cells and planted into 96-well plates. Monoclones were selected for amplification and then assessed by Western blot assays using anti-flag antibody (Sigma-Aldrich, USA).
In vivo subcutaneous xenograft analysis
The animal use and the experiment protocol were approved by the Institutional Animal Care and Use Committee of Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University. Subcutaneous xenograft models were established as previously described . Nude mice were randomly divided into control, WT and E545K mutation groups that received subcutaneous injection inoculations with 1 × 106 NOZ, NOZ-WT and NOZ-E545K cells, respectively. The tumor volumes were measured using Vernier calipers once every three days, and the tumor volumes were calculated according to the following formula: tumor volume (mm3) = L × W2 (where L and W represent the length and width of the tumor, respectively). On day 21, the mice were anesthetized and photographed. Afterwards, the mice in the control group were sacrificed. The WT group and the E545K mutation group were randomly divided into A66 group and normal saline groups. The mice in the A66 group were injected with 1 mg A66 once every three days through the tail vein for three weeks, and the mice in normal saline group were injected with same volume of normal saline. The tumor volumes were measured once every three days as previously described. On day 42, the mice were sacrificed, and the tumor tissues were removed and weighed.
Three weeks after treated with A66 or NS, the mice were sacrificed and the tumors were dissected out. The PI3K p110α expression and proliferative index of Ki-67 was evaluated in xenograft tumors by immunohistochemical staining (IHC). IHC staning was performed as previously described .
SPSS 18.0 software was used to perform the statistical analyses. All values are expressed as the mean ± the standard deviation (SD) unless otherwise stated. Student’s t-tests were performed to compare the differences between the different experiment groups unless otherwise stated. P-values less than 0.05 were considered statistically significant (P < 0.05 is denoted by *).
We thank Bert Vogelstein for providing the PIK3CA wild type and E545K mutation plasmids. This study was supported by the National Natural Science Foundationof China (Nos. 81172026, 81272402, 81301816, 81172029, 91440203 and 81402403), the National High Technology Research and Development Program (863 Program, No. 2012AA022606), the Foundation for Interdisciplinary Research of Shanghai Jiao Tong University (No. YG2011ZD07), the Shanghai Science and Technology Commission Intergovernmental International Cooperation Project (No. 12410705900), the Shanghai Science and Technology Commission Medical Guiding Project (No. 12401905800), the Program for Changjiang Scholars, the Natural Science Research Foundation of Shanghai Jiao Tong University School of Medicine (No. 13XJ10037), the Leading Talent program of Shanghai and Specialized Research Foundation for the PhD Program of Higher Education-Priority Development Field (No. 20130073130014), the Interdisciplinary Program of Shanghai Jiao Tong University (No. 14JCRY05), the Shanghai Rising-Star Program (No. 15QA1403100), and the China Postdoctoral Science Foundation (No. 2015 M571577).
LC, JZ and YL designed this research, SZ designed the experimental setup, SZ, YC and SL performed the experiments, XW, RB, YS, YH performed the Western blot experiments, YZ, LJ, FZ, HL, HL, QM, YX, ZW, YZ analysed the data, SZ wrote this manuscript. All authors read and approved the final version.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Weng H et al. Zinc finger X-chromosomal protein (ZFX) is a significant prognostic indicator and promotes cellular malignant potential in gallbladder cancer. Cancer Biol Ther. 2015;16:1462–70. doi:10.1080/15384047.2015.1070994.View ArticlePubMedGoogle Scholar
- Cao Y et al. Fibronectin promotes cell proliferation and invasion through mTOR signaling pathway activation in gallbladder cancer. Cancer Lett. 2015;360:141–50. doi:10.1016/j.canlet.2015.01.041.View ArticlePubMedGoogle Scholar
- Liu TY et al. Baicalein inhibits progression of gallbladder cancer cells by downregulating ZFX. PLoS One. 2015;10:e0114851. doi:10.1371/journal.pone.0114851.View ArticlePubMedPubMed CentralGoogle Scholar
- Weng H et al. Ursolic acid induces cell cycle arrest and apoptosis of gallbladder carcinoma cells. Cancer Cell Int. 2014;14:96. doi:10.1186/s12935-014-0096-6.View ArticlePubMedPubMed CentralGoogle Scholar
- Bayer R, Galea S. Public health in the precision-medicine era. N Engl J Med. 2015;373:499–501. doi:10.1056/NEJMp1506241.View ArticlePubMedGoogle Scholar
- Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606–19. doi:10.1038/nrg1879.View ArticlePubMedGoogle Scholar
- Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 2005;5:921–9. doi:10.1038/nrc1753.View ArticlePubMedGoogle Scholar
- Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627–44. doi:10.1038/nrd2926.View ArticlePubMedPubMed CentralGoogle Scholar
- Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655–7. doi:10.1126/science.296.5573.1655.View ArticlePubMedGoogle Scholar
- Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11:329–41. doi:10.1038/nrm2882.View ArticlePubMedGoogle Scholar
- Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4:988–1004. doi:10.1038/nrd1902.View ArticlePubMedGoogle Scholar
- Juric D et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature. 2015;518:240–4. doi:10.1038/nature13948.View ArticlePubMedGoogle Scholar
- Bosch A et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med. 2015;7:283ra251. doi:10.1126/scitranslmed.aaa4442.View ArticleGoogle Scholar
- Elkabets M et al. AXL mediates resistance to PI3Kalpha inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell. 2015;27:533–46. doi:10.1016/j.ccell.2015.03.010.View ArticlePubMedPubMed CentralGoogle Scholar
- Dail M et al. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature. 2014;513:512–6. doi:10.1038/nature13495.View ArticlePubMedPubMed CentralGoogle Scholar
- Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A. 2005;102:802–7. doi:10.1073/pnas.0408864102.View ArticlePubMedPubMed CentralGoogle Scholar
- Samuels Y et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554. doi:10.1126/science.1096502.View ArticlePubMedGoogle Scholar
- Song Y et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91–5. doi:10.1038/nature13176.View ArticlePubMedGoogle Scholar
- Waddell N et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495–501. doi:10.1038/nature14169.View ArticlePubMedPubMed CentralGoogle Scholar
- Jiao Y et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45:1470–3. doi:10.1038/ng.2813.View ArticlePubMedPubMed CentralGoogle Scholar
- Li M et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014;46:872–6. doi:10.1038/ng.3030.View ArticlePubMedGoogle Scholar
- Boucrot E et al. Endophilin marks and controls a clathrin-independent endocytic pathway. Nature. 2015;517:460–5. doi:10.1038/nature14067.View ArticlePubMedGoogle Scholar
- Lemke J et al. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Differ. 2014;21:491–502. doi:10.1038/cdd.2013.179.View ArticlePubMedGoogle Scholar
- Utermark T et al. The p110alpha and p110beta isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev. 2012;26:1573–86. doi:10.1101/gad.191973.112.View ArticlePubMedPubMed CentralGoogle Scholar
- Hu YP et al. Triptolide induces s phase arrest and apoptosis in gallbladder cancer cells. Molecules. 2014;19:2612–28. doi:10.3390/molecules19022612.View ArticlePubMedGoogle Scholar
- Bao R et al. Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway. BMC Cancer. 2014;14:1–13.View ArticleGoogle Scholar
- Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501. doi:10.1038/nrc839.View ArticlePubMedGoogle Scholar
- Hao Y et al. Gain of interaction with IRS1 by p110alpha-helical domain mutants is crucial for their oncogenic functions. Cancer Cell. 2013;23:583–93. doi:10.1016/j.ccr.2013.03.021.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhao JJ et al. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A. 2005;102:18443–8. doi:10.1073/pnas.0508988102.View ArticlePubMedPubMed CentralGoogle Scholar
- Isakoff SJ et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005;65:10992–1000. doi:10.1158/0008-5472.can-05-2612.View ArticlePubMedGoogle Scholar
- Vadas O, Burke JE, Zhang X, Berndt A, Williams RL. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal. 2011;4:re2. doi:10.1126/scisignal.2002165.View ArticlePubMedGoogle Scholar
- Amzel LM et al. Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer. 2008;8:665–9. doi:10.1038/nrc2443.View ArticlePubMedPubMed CentralGoogle Scholar
- Huang CH et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science. 2007;318:1744–8. doi:10.1126/science.1150799.View ArticlePubMedGoogle Scholar
- Miled N et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science. 2007;317:239–42. doi:10.1126/science.1135394.View ArticlePubMedGoogle Scholar
- Li M et al. Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway. Cancer Lett. 2014;355:201–9. doi:10.1016/j.canlet.2014.08.036.View ArticlePubMedGoogle Scholar